NASDAQ : CGEN
Compugen Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 1.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 187.55M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 187.55M |
| Enterprise Value | 65.28M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 94.72M |
| Shares Outstanding | 94.72M |
| Shares Change (YoY) | +3.76% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.22% |
| Owned by Institutions (%) | 16.34% |
| Float | 94.51M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 5.30 |
| Forward PE | n/a |
| PS Ratio | 2.53 |
| Forward PS | 34.84 |
| PB Ratio | 2.11 |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | 6.67 |
| P/OCF Ratio | 6.64 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 1.85 |
| EV / Sales | 0.88 |
| EV / EBITDA | 2.13 |
| EV / EBIT | 2.15 |
| EV / FCF | 2.32 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.72 |
| Quick Ratio | 5.72 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.10 |
| Debt / FCF | 0.11 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 50.64% |
| Return on Assets (ROA) | 15.46% |
| Return on Invested Capital (ROIC) | 26.12% |
| Return on Capital Employed (ROCE) | 26.18% |
| Weighted Average Cost of Capital (WACC) | 19.28% |
| Revenue Per Employee | $986,680 |
| Profits Per Employee | $469,213 |
| Employee Count | 75 |
| Asset Turnover | 0.60 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 52,000 |
| Effective Tax Rate | 0.15% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.79 |
| 52-Week Price Change | +20.00% |
| 50-Day Moving Average | 2.32 |
| 200-Day Moving Average | 2.30 |
| Relative Strength Index (RSI) | 41.26 |
| Average Volume (20 Days) | 240,549 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.52M |
| Short Previous Month | 2.35M |
| Short % of Shares Out | 2.66% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 13.90 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 74.00M |
| Gross Profit | 64.30M |
| Operating Income | 30.30M |
| Pretax Income | 35.24M |
| Net Income | 35.19M |
| EBITDA | 30.68M |
| EBIT | 30.30M |
| Earnings Per Share (EPS) | $0.37 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 125.30M |
| Total Debt | 3.02M |
| Net Cash | 122.28M |
| Net Cash Per Share | $1.29 |
| Equity (Book Value) | 88.73M |
| Book Value Per Share | 0.94 |
| Working Capital | 106.78M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 28.25M |
| Capital Expenditures | -116,000 |
| Depreciation & Amortization | 380,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 28.14M |
| FCF Per Share | $0.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.89% |
| Operating Margin | 40.94% |
| Pretax Margin | 47.63% |
| Profit Margin | 47.55% |
| EBITDA Margin | 41.45% |
| EBIT Margin | 40.94% |
| FCF Margin | 38.02% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.76% |
| Shareholder Yield | -3.76% |
| Earnings Yield | 18.85% |
| FCF Yield | 15.00% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.60 |
| Price Target Difference | 132.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -37.20% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.4 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |